The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

Beyond technology, regulations weigh heavily on the minds of pharma executives. Four out of 10 leaders believe regulatory ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

Lilly announced several changes to its executive leadership team. 1 These changes are mostly related to the company’s ...

In an effort to combat the state’s shortage of primary care physicians, Blue Cross Blue Shield of Massachusetts is offering ...

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and ...

The idea of creating a gray zone in the payer message is to take the onus off of having to heavily discount for equal access ...

Kapil Raina, MD, Principal of Market Access at Herspiegel Consulting, talks about disconnects in the industry, how patients ...

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...

Commissioner Markary announced the plans alongside the results of a generative AI pilot for scientific reviewers.

With this is mind, Abbott announced a new program that combines one of the most popular sports in the world with education ...